Anti-apoptotic role of Bfl-1 in staurosporine-treated B-lymphoblastic cells

Int J Hematol. 2000 Dec;72(4):484-90.

Abstract

To examine the relationship between the expression level of Bfl-1 and the susceptibility to staurosporine-induced apoptosis in B-lymphoblastic cells, we tested cell survival in 4 cell lines: 2 that are Bfl-1-nonexpressing (Reh and JM-1) and 2 that are Bfl-1-expressing (IM-9 and Wil2-NS). Reh and JM-1 showed apoptosis levels of 62% (Reh) and 30% (JM-1) as early as 3 hours after treatment with staurosporine, whereas IM-9 and Wil2-NS showed apoptosis levels of only 40% and 26%, respectively, even after 1 day of treatment with staurosporine. Either induced expression of Bfl-1 with 12-o-tetradecanoyl phorbol-13-acetate or exogenous expression of Bfl-1 by transfection in Reh cells promoted cell survival. These results suggest that expression of Bfl-1 contributes to regulating apoptosis in the B-cell lines we examined.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects*
  • B-Lymphocytes / drug effects*
  • B-Lymphocytes / physiology
  • Gene Expression
  • Genes, bcl-2
  • Hematopoietic Stem Cells / drug effects
  • Hematopoietic Stem Cells / physiology
  • Humans
  • Minor Histocompatibility Antigens
  • Multigene Family / genetics
  • Proteins / genetics
  • Proteins / pharmacology*
  • Proteins / physiology
  • Proto-Oncogene Proteins c-bcl-2*
  • Staurosporine / pharmacology*
  • Tumor Cells, Cultured

Substances

  • BCL2-related protein A1
  • Minor Histocompatibility Antigens
  • Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Staurosporine